Economics of Transfusion Medicine and Blood Conservation Practices

  • Karl H. Krieger
  • O. Wayne Isom
  • Ferdinand T. Velasco


The health care industry today is undergoing radical changes in its economic architecture. Spiraling costs have prompted a widespread movement to reform the health care delivery system. In addition to legislative reform, there are significant market forces driving this process. Increasingly, the industry has shifted to a managed care model and a prospective payment system. Declining revenues have impelled hospitals to seek greater cost-effectiveness.


Chest Drainage Cell Saver Blood Conservation Autologous Blood Donation York Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wallace EL. Costing blood products and services (editorial). Transfusion 1991;31:293–295.PubMedCrossRefGoogle Scholar
  2. 2.
    Wallace EL, Wallace MA. Hospital Transfusion Charges and Community Blood Center Costs, Prepared Under Contract with the National Heart, Lung, and Blood Institute Bethesda, MD: NHLBI, 1982.Google Scholar
  3. 3.
    Cumming PD, Wallace EL, Surgenor DM, et al. Public interest pricing of blood services. Med Care 1974;12:743–753.PubMedCrossRefGoogle Scholar
  4. 4.
    Zuck TF. An hypothesis on the cost effectiveness of homologous blood transfusions in 1988. Transfus Med Rev 1988;2:245–249.PubMedCrossRefGoogle Scholar
  5. 5.
    Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991;31:318–323.PubMedCrossRefGoogle Scholar
  6. 6.
    Lubarsky DA, Hahn C, Bennett D, et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg 1994;79:629–637.PubMedCrossRefGoogle Scholar
  7. 7.
    New York Blood Center Fee Schedule. New York, NY, 1993.Google Scholar
  8. 8.
    Birkmeyer JD, Goodnough LT, AuBuchon JP, et al. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544–551.PubMedCrossRefGoogle Scholar
  9. 9.
    Scott WJ, Rode R, Castlemain B, et al. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 1992;103:1001–1007.PubMedGoogle Scholar
  10. 10.
    Baele PL, Ruiz-Gomez J, Londot C, et al. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesth Belg 1992;43:103–112.PubMedGoogle Scholar
  11. 11.
    Stevens ME, Summerfield GP, Hall AA, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992;304:474–477.CrossRefGoogle Scholar
  12. 12.
    Sheingold SH, Churchill DN, Muirhead N, Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis (editorial). Am J Kidney Dis 1991;17:86–92.PubMedGoogle Scholar
  13. 13.
    Hayashi J, Kumon K, Takanashi S, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double-blind, multicenter trial in Japan. Transfusion 1994;34:142–146.PubMedCrossRefGoogle Scholar
  14. 14.
    Strauss RG. Can the cost of erythropoietin for cardiac surgery patients be justified? (letter). Transfusion 1994;34:835.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • Karl H. Krieger
  • O. Wayne Isom
  • Ferdinand T. Velasco

There are no affiliations available

Personalised recommendations